ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Resident Macrophage-Orchestrated Immune and Fibroblast Interactions in Immune Checkpoint Inhibitor-Associated Nephrotoxicity.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Risk stratification for immune checkpoint inhibitor rechallenge after acute kidney injury: towards a precision medicine framework.Frontiers in immunology · 2026Review
- Resident Macrophage-Orchestrated Immune and Fibroblast Interactions in Immune Checkpoint Inhibitor-Associated Nephrotoxicity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The multifaceted role of macrophages in kidney physiology and diseases.Frontiers in immunology · 2025Review
- Urgent considerations on renal immune-related adverse events in oncology practice.Frontiers in immunology · 2025Review
- Single-Cell and Spatial Transcriptomics in Renal Injury and Fibrosis Research.Kidney diseases (Basel, Switzerland)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Immune checkpoint inhibitors (ICIs) transform cancer therapy but are often associated with immune-related adverse events, including ICI-associated nephrotoxicity (ICI-AN). The mechanisms driving ICI-AN remain poorly understood, limiting diagnostic and therapeutic progress. This study integrates imaging mass cytometry, transcriptomics, and murine models to investigate the cellular and molecular mechanisms driving ICI-AN. Kidney biopsies from ICI-AN patients show increased resident macrophages, fibroblasts, and CD8⁺ T cells, with resident macrophages exhibiting elevated pro-inflammatory and pro-fibrotic markers. In mice, anti-PD-1 treatment induces renal injury characterized by immune cell infiltration, tubular injury, and fibrosis. Depletion of resident macrophages reduces CXCL9 and MMP12 expression, alleviating renal injury without compromising anti-tumor effects. Transcriptomic analysis confirms that inflammatory and fibrotic pathways involving CXCL9 and MMP12 are central to ICI-AN pathogenesis. Urinary CXCL9 levels are significantly elevated in ICI-AN patients, correlating with tubular injury and resident macrophage abundance, while MMP12 expression is predominantly localized to resident macrophages. Pharmacological inhibition of MMP12 mitigates renal injury. These results highlight resident macrophages as central drivers of ICI-AN and identify CXCL9 as a potential diagnostic biomarker and MMP12 as a therapeutic target. This study provides new insights into ICI-AN pathogenesis and offers strategies to mitigate nephrotoxicity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.